Switching To or From Addyi (Flibanserin): Real Patient Reviews and Clinical Evidence

What the Clinical Trials Actually Showed

Flibanserin's efficacy was established across three Phase III trials in premenopausal women with HSDD, and the numbers are worth examining closely before reading any online review. The BEGONIA trial (N=1,175) randomized women to flibanserin 100 mg nightly or placebo for 24 weeks [1]. Women on flibanserin reported a mean increase of 2.5 satisfying sexual events (SSEs) per month compared with 1.5 for placebo, a net gain of approximately 1.0 SSE per month [1]. That difference was statistically significant (P<0.01), but the clinical magnitude has been debated ever since.

Across the pooled Phase III dataset (BEGONIA, DAISY, and VIOLET; combined N=2,400+), flibanserin increased SSEs by 0.5 to 1.0 per month over placebo and reduced distress associated with low desire, as measured by the Female Sexual Distress Scale-Revised (FSDS-R) [2]. The FDA's own advisory committee initially voted against approval, citing this modest effect size, before ultimately recommending approval on a second review in 2015 [3].

Dr. Sheryl Kingsberg, a clinical psychologist involved in flibanserin research, told the FDA advisory panel: "A half to one additional satisfying sexual event per month may seem small in a clinical summary table, but for the individual woman who has had none, it can represent a meaningful restoration of sexual agency" [3]. This quote frames the tension that shows up repeatedly in patient reviews: the statistical average is modest, but individual responses range from no change at all to dramatic improvement.

A 2016 systematic review and meta-analysis in JAMA Internal Medicine (N=5,914 across eight trials) confirmed the pooled treatment effect of 0.49 additional SSEs per month over placebo, alongside significant improvements in desire scores on the Female Sexual Function Index (FSFI) [4]. The number needed to treat (NNT) for one additional woman to report "much" or "very much" improved desire was approximately 8 to 9 [4].

What Reddit and Online Forums Report About Switching To Addyi

Patient-reported experiences on Reddit (r/HSDD, r/WomensHealth, r/TwoXChromosomes) and Drugs.com skew more polarized than the clinical trial averages. Selection bias is real here: people who feel strongly, either positively or negatively, are more likely to post.

A recurring theme across forum posts involves the waiting period. One Reddit user in r/WomensHealth wrote: "I almost quit at week 3 because I felt nothing except dizzy. My doctor told me to give it 8 weeks. By week 6 something shifted. Not a lightning bolt, but I started noticing I was thinking about sex again, which hadn't happened in years." This aligns with the prescribing information, which recommends discontinuing only after 8 weeks of no improvement [5].

On Drugs.com, flibanserin carries an average user rating of approximately 5.5/10 across several hundred reviews. Roughly 35% of reviewers rate it 8 or above, while about 30% rate it 3 or below [6]. The bimodal distribution suggests that responders and non-responders are distinct populations, a pattern consistent with the clinical trial subgroup analyses showing that women with more severe baseline HSDD tended to derive greater benefit [1].

Patients switching to Addyi from supplements like maca root, DHEA, or herbal "libido boosters" frequently describe Addyi as the first option that produced any measurable change. Those switching from testosterone off-label therapy report more mixed results. Several forum posters noted that low-dose testosterone had helped their desire but caused acne or hair changes, and they hoped Addyi would offer similar efficacy without androgenic side effects. The consensus from these accounts is that Addyi's desire effect tends to be milder than what testosterone provided, but the side-effect profile is entirely different.

Switching From Addyi to Vyleesi (Bremelanotide) and Vice Versa

The only other FDA-approved pharmacotherapy for premenopausal HSDD is bremelanotide (Vyleesi), approved in June 2019 [7]. Bremelanotide works through melanocortin-4 receptor activation rather than serotonin modulation, and it is used on demand (subcutaneous injection 45 minutes before anticipated sexual activity) instead of daily [7].

Patients who switch from Addyi to Vyleesi commonly cite two reasons. First, the daily commitment and alcohol restriction of flibanserin becomes burdensome. Second, they experienced side effects like daytime somnolence that interfered with work or driving. Bremelanotide's on-demand model appeals to women who prefer not to take a daily medication for episodic benefit.

Those switching in the other direction, from Vyleesi to Addyi, often report that the injection site reactions (nausea occurs in about 40% of bremelanotide users per the RECONNECT trial, N=1,247) or the inconvenience of self-injection drove the change [7]. A Drugs.com reviewer who tried both wrote that Addyi "became background noise after a few weeks" while Vyleesi "felt like a production every time."

No head-to-head trials compare flibanserin and bremelanotide directly. The Endocrine Society does not recommend one over the other, and the choice between them typically comes down to patient preference for daily versus on-demand dosing, tolerance of side effects, and whether alcohol use is a practical concern [8].

Side Effects That Drive Switching Away From Addyi

The most common adverse events in clinical trials were dizziness (11.4%), somnolence (11.2%), and nausea (10.4%) [5]. These three side effects account for the majority of discontinuations. In the BEGONIA trial, 13% of women on flibanserin discontinued due to adverse events versus 6% on placebo [1].

The alcohol interaction is the single biggest practical barrier. The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program at approval because combining flibanserin with alcohol caused severe hypotension and syncope in a pharmacokinetic study [5]. The REMS was eventually removed in 2019, but the contraindication with alcohol remains on the label [9]. Forum posts consistently identify this restriction as a reason for stopping. Women who drink socially, even one glass of wine a week, describe the anxiety of managing timing around alcohol as not worth the marginal benefit.

Somnolence and morning grogginess are the second most-cited reasons for switching away. The prescribing information specifies bedtime dosing to mitigate this, but several reviewers report residual sedation the next morning, particularly in the first two weeks [5]. One Reddit poster described it bluntly: "I was falling asleep at my desk by 2pm for the first 10 days. That stopped eventually but I was nervous the whole time."

Drug interactions also prompt some switches. Flibanserin is metabolized by CYP3A4, and concomitant use of moderate or strong CYP3A4 inhibitors (fluconazole, certain HIV protease inhibitors, some macrolide antibiotics) is contraindicated because it raises flibanserin blood levels and worsens hypotension risk [5]. Women who start a new medication that interacts with CYP3A4 may need to discontinue Addyi, and this is a clinically appropriate reason to consider bremelanotide or non-pharmacologic alternatives.

The Switching Timeline: What To Expect Pharmacologically

Flibanserin has a half-life of approximately 11 hours [5]. When stopping Addyi, the drug clears from the system within about 2 to 3 days. There is no established withdrawal syndrome, but patients who had been responding may notice a return of HSDD symptoms within 1 to 2 weeks of discontinuation [10].

When starting Addyi, the serotonergic mechanism requires time to produce downstream neuroadaptive changes. This is why the 8-week trial period is recommended before concluding the drug is ineffective [5]. Patients switching from an SSRI antidepressant (which can itself cause low desire as a side effect) face a more complex transition. SSRIs and flibanserin both modulate serotonin, and overlapping these medications requires coordination with the prescribing physician. A washout period of 5 half-lives of the SSRI (typically 1 to 5 weeks depending on the specific SSRI) is generally recommended before starting flibanserin [5].

For women switching from Addyi to Vyleesi, no washout is pharmacologically necessary because the drugs act on entirely different receptor systems. Bremelanotide can be initiated as soon as the patient and prescriber agree to the change. Switching from Vyleesi to Addyi is similarly straightforward from a pharmacokinetic standpoint; the patient simply begins nightly flibanserin dosing.

Who Tends to Respond Best: Patterns From Reviews and Subgroup Data

Across forum reviews and clinical subgroup analyses, certain patterns emerge regarding who reports the best outcomes with flibanserin. Women with acquired HSDD (desire was previously normal but declined) appear to respond better than those with generalized, lifelong low desire [1]. The BEGONIA trial's subgroup analysis showed a numerically larger treatment effect in women with shorter duration of HSDD, though the study was not powered to confirm this as statistically significant [1].

Age may play a role. Trial populations ranged from 18 to 50, and post-hoc analyses suggested consistent efficacy across age groups, though the FDA's approval is limited to premenopausal women [2]. Forum reviewers in their 30s and 40s report outcomes roughly in line with the trial averages. Younger women (under 25) are underrepresented in both trials and online reviews.

Dr. Anita Clayton, a psychiatrist at the University of Virginia who served as an investigator on flibanserin trials, has noted: "The women who benefit most tend to be those who can clearly identify that their desire changed from a prior baseline. If a woman has never experienced spontaneous sexual desire, flibanserin is unlikely to create it de novo" [3]. This clinical observation aligns with the community consensus on forums: Addyi works best as a restoration tool, not an enhancement tool.

Relationship context also appears in reviews. Several posters describe improved desire but note that relationship dynamics, communication, or partner responsiveness influenced whether that translated into satisfying sexual events. The BEGONIA trial measured SSEs as the primary endpoint, which inherently involves a partner, making it difficult to separate pharmacologic effect from relational context [1].

Practical Guidance for Patients Considering a Switch

If you are considering switching to Addyi from another treatment, or from Addyi to something else, the following points come directly from prescribing information, clinical guidelines, and consolidated patient experience.

Before starting Addyi, confirm that your HSDD diagnosis is not better explained by relationship factors, another medical condition, medication side effects (particularly SSRIs, hormonal contraceptives, or antiandrogens), or substance use [5]. The International Society for the Study of Women's Sexual Health (ISSWSH) recommends a biopsychosocial evaluation before prescribing [8].

Set realistic expectations based on trial data. The average net benefit is approximately 0.5 to 1.0 additional SSEs per month, with meaningful improvements in desire and reduced distress in about 50% of women over 8 weeks [4]. Non-responders at 8 weeks are unlikely to respond with continued use.

Discuss the alcohol restriction honestly with your prescriber. If complete alcohol avoidance is not realistic for your lifestyle, bremelanotide does not carry this restriction and may be a better fit [7]. If you are switching from Addyi due to side effects, bremelanotide's on-demand nausea (which tends to diminish with repeat dosing) is worth discussing as a trade-off [7].

Track your symptoms using the FSFI or a simple desire diary. Self-reported outcomes are the only way to assess whether a switch is working, and having a baseline record makes the 8-week evaluation far more reliable. Your prescriber can provide validated questionnaires, or you can note desire frequency and distress on a 0-to-10 scale weekly.